Related Experiment Video
Updated: Feb 16, 2026

08:59
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
Published on: January 5, 2017
11.4K
Mathematical model of perineural tumor spread: a pilot study
Joshua J Jacobs1, Stepan Capek2, Robert J Spinner1
1Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA.
Acta Neurochirurgica
|December 22, 2017
Summary
This study introduces a mathematical model to predict the spread of pelvic cancer along nerves, aiding in the diagnosis and treatment of neoplastic lumbosacral plexopathy (nLSP). The model successfully visualized tumor growth, offering a new tool for disease monitoring.
Area of Science:
- Oncology
- Medical Imaging
- Mathematical Modeling
Background:
- Perineural spread (PNS) of pelvic cancer along the lumbosacral plexus causes neoplastic lumbosacral plexopathy (nLSP), leading to significant patient morbidity and mortality.
- Diagnosing and treating PNS in recurrent tumors presents a clinical challenge due to its complex nature.
Purpose of the Study:
- To develop and present a mathematical model for predicting the course and extent of perineural tumor spread.
- To adapt existing mathematical models for glioblastoma multiforme (GBM) to model recurrent pelvic tumor spread along the lumbosacral plexus.
Main Methods:
- Created 3D models of perineural tumor spread using MRI scans from two patients with pelvic cancer (prostate and cervical).
- Adapted a mathematical model of GBM to simulate tumor progression along the nerves on an anatomical model.
Main Results:
- Successfully modeled and visualized perineural spread of pelvic cancer in two patients.
- Calculated average tumor growth rates of 60.7 mm/year and 129 mm/year.
- Demonstrated good correlation between the model's predictions and the extent of PNS observed on MRI scans.
Conclusions:
- This is the first mathematical model developed for perineural tumor spread, offering a novel approach to disease progression monitoring.
- The model provides a foundation for future integration of mathematical tools in personalized medicine for cancer treatment response assessment.
- Highlights the need for unified scales, like 'days gained,' for reporting treatment response in the era of individualized medicine.

